What Is The Current and Historic Market Size Analysis Of The CRISPR Gene Editing Market?
The crispr gene editing market has seen considerable growth due to a variety of factors.
• The CRISPR gene editing market has grown exponentially in recent years. It is projected to grow from $2.26 billion in 2024 to $2.88 billion in 2025, at a compound annual growth rate (CAGR) of 27.4%.
This rapid growth is attributed to increased demand for genome editing technologies, higher government funding, the rising prevalence of cancer and chronic diseases, and growing awareness of CRISPR technology.
What Is The Forecast For The CRISPR Gene Editing Market Size?
The crispr gene editing market is expected to maintain its strong growth trajectory in upcoming years.
• The CRISPR gene editing market is anticipated to experience rapid expansion, reaching $7.51 billion by 2029 at a CAGR of 27.1%.
Growth drivers include the increasing prevalence of genetic disorders, greater focus on precision medicine, rising investments in CRISPR R&D, the aging population, and the growing demand for gene therapy. Major trends include advancements in gene editing technologies, more research studies, innovations in drug discovery and delivery methods, and the adoption of CRISPR-edited agriculture.
What Are The Essential Drivers Behind The Growth Of The CRISPR Gene Editing Market?
The rising prevalence of genetic disorders is expected to accelerate the growth of the CRISPR gene editing market. Genetic disorders, caused by mutations in genes or chromosomes, are becoming more common due to factors like aging populations and consanguineous marriage. CRISPR technology helps manage these disorders by allowing precise modifications to the DNA to correct mutations, offering potential treatments for conditions like cystic fibrosis and sickle cell anemia. For example, in July 2022, the Cystic Fibrosis Foundation reported that cystic fibrosis affects nearly 40,000 people in the US. The increasing prevalence of genetic disorders drives the CRISPR gene editing market.
How Is The Global CRISPR Gene Editing Market Divided Into Key Segments?
The CRISPR gene editing market covered in this report is segmented –
1) By Type: CRISPR-Associated Nuclease (Cas Nuclease), Guide Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA) Ligase, Restriction Endonuclease, Other Types
2) By Services: Design Tools, Plasmid And Vector, CRISPR-Associated Protein 9 (Cas
9) And Guide Ribonucleic Acid (g-RNA), Delivery System Products, Other Services
3) By Technology: CRISPR Or Cas9, Zinc Finger Nucleases, Other Technologies
4) By Application: Agricultural, Biomedical, Industrial, Genome Engineering, Disease Models, Functional Genomics, Other Applications
5) By End User: Academic Institutes And Research Centers, Biotechnology Companies, Contract Research Organizations (CROs), Pharmaceutical And Biopharmaceutical Companies
Subsegments:
1) By CRISPR-Associated Nuclease (Cas Nuclease): Cas9, Cas12, Cas13, Other Cas Nucleases
2) By Guide Ribonucleic Acid (RNA): Single-guide RNA (sgRNA), Dual-guide RNA, Synthetic Guide RNA
3) By Deoxyribonucleic Acid (DNA) Ligase: T4 DNA Ligase, E. coli DNA Ligase, Other DNA Ligases
4) By Restriction Endonuclease: Type II Restriction Enzymes, Type I And III Restriction Enzymes, Other Restriction Enzymes
5) By Other Types: CRISPR Delivery Systems, CRISPR Plasmids, CRISPR-Based Diagnostic Tools
Pre-Book The CRISPR Gene Editing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The CRISPR Gene Editing Market?
Companies in the CRISPR gene editing market are focusing on products like gene therapy to cater to a broader customer base, drive sales, and boost revenue. Gene therapy involves using genes to treat or cure diseases. For example, in December 2023, the FDA approved Casgevy, a cell-based gene therapy using CRISPR/Cas9 technology, to treat sickle cell disease by modifying hematopoietic stem cells.
Who Are the Key Players In The CRISPR Gene Editing Market?
Major companies operating in the CRISPR gene editing market are:
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Agilent Technologies Inc.
• GenScript
• Integrated DNA Technologies Inc.
• Takara Bio Inc.
• OriGene Technologies Inc.
• Intellia Therapeutics Inc.
• New England Biolabs
• Synthego
• Arbor Biotechnologies Inc.
• Rockland Immunochemicals Inc.
• Cellectis
• Editas Medicine
• Caribou Biosciences Inc.
• System Biosciences LLC
• Applied StemCell
• Addgene
• Mirus Bio LLC
• Excision BioTherapeutics Inc.
• GeneCopoeia Inc.
• ToolGen Inc.
• Cellecta Inc.
• CRISPR Therapeutics
• ERS Genomics Limited
What Are The Regional Insights Into The CRISPR Gene Editing Market?
North America was the largest region in the CRISPR gene editing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the CRISPR gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
